Predictors of early mortality in implantable cardioverter-defibrillator recipients

Europace

Volumn 11, Issue 6, 2009, Pages 734-740

  Stein, Kenneth M ^a   Mittal, Suneet ^b   Gilliam, F Roosevelt ^c   Gilligan, David M ^d   Zhong, Qian ^e   Kraus, Stacia Merkel ^f   Meyer, Timothy E ^g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c Cardiology Associates of NE Arkansas ^*  (United States)

^d Virginia Cardiovascular Specialists   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Integra Group   (United States)

^g Boston Scientific CRM   (United States)

Author keywords

Implantable cardioverter defibrillators (ICDs); Mortality; Risk stratification

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DIGITALIS; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BODY MASS; CARDIAC PATIENT; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DEFIBRILLATOR; DEMOGRAPHY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE REGISTRY; FEMALE; FOLLOW UP; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT INFORMATION; PHYSICAL ACTIVITY; PREDICTOR VARIABLE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; HEART FAILURE; HUMANS; INCIDENCE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 67651068260     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eup055     Document Type: Article

References (36)

1. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997; 337:1576-83.
2. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable car-dioverter defibrillator against amiodarone. Circulation 2000;101:1297-302.
3. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-54.
4. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. The Multi-center Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
5. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al., for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators . Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
6. Peppercorn JM, Weeks JC, Cook EF, Joffe S. Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. Lancet 2004;363:263-70.
7. Davis S, Wright PW, Schulman SF, Hill LD, Pinkman RD, Johnson LP et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985;56:1710-8.
8. Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J 2006;151:397-403.
9. Lee DS, Tu V, Austin PC, Dorian P, Yee R, Chong A et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007;49:2408-15.
10. Schernthaner C, Pichler M, Strohmer B. Lower body mass index and atrial fibrillation as independent predictors for mortality in patients with implantable cardioverter defibrillator. Croat Med J 2007;48:59-67.
11. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306: 1018-22.
12. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-52.
13. Bigger JT Jr. Epidemiological and mechanistic studies of atrial fibrillation as a basis for treatment strategies. Circulation 1998;98:943-5.
14. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:1116-43.
15. Ahmed A. A propensity matched study of New York Heart association class and natural history end points in heart failure. Am J Cardiol 2007;99:549-53.
16. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A et al. The prognosis of heart failure in the general population: the Rotterdam Study. Eur Heart J 2001;22:1318-27.
17. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001;38:789-95.
18. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LAM, Skali H et al., for the CHARM Investigators. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program. Circulation 2007;116: 627-36.
19. Lissin LW, Gauri AJ, Froelicher VF, Ghayoumi A, Myers J, Giacommini J. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. J Card Fail 2002;8:206-15.
20. Davos CH, Doehner W, Rauchhaus M, Cicoira M, Francis DP, Coats AJS et al. Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail 2003;9:29-35.
21. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003;91:891-4.
22. Curtis JP, Selter JG, Wang Y, Rathore SS, Jovin IS, Jadbabaie F et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005;165:55-61.
23. Gustafsson F, Kragelund CB, Torp-Pedersen C, Seibaek M, Burchardt H, Akkan D et al., DIAMOND Study Group. Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. Eur Heart J 2005;26:58-64.
24. Bozkurt B, Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J 2005;150:1233-9.
25. Kalantar-Zadeh K, Block G, Horwich T, Fonorow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004;43:1439-44.
26. Habbu A, Lakkis MN, Hisham D. The obesity paradox: fact or fiction? Am J Cardiol 2006;98:944-8.
27. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989;261:884-8.
28. Sahebjami H, Gartside PS. Pulmonary function in obese subjects with a normal FEV1/FVC. Chest 1996;110:1425-9.
29. Caruana L, Petrie MC, Davie AP, McMurray JJV. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from 'diastolic heart failure' or from misdiagnosis? A prospective descriptive study. BMJ 2000;321: 215-8.
30. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293:1861-7.
31. Wittenberg SM, Cook JR, Hall WJ, McNitt S, Zareba W, Moss AJ, Multicenter Automatic Defibrillator Implantation Trial. Comparison of efficacy of implanted cardioverter-defibrillator in patients with versus without diabetes mellitus. Am J Cardiol 2005;96:417-9.
32. Cowburn PJ, Cleland JG, Coats AJ, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998;19:696-710.
33. Voigt A, Ezzeddine R, Barrington W, Obiaha-Ngwu O, Ganz LI, London B et al. Utilization of implantable cardioverter-defibrillators in survivors of cardiac arrest in the United States from 1996 to 2001. J Am Coll Cardiol 2004;44: 855-8.
34. Huang DT, Sesselberg HW, Mcnitt S, Noyes K, Andrews ML, Hall WJ et al., for the MADIT-II Research Group. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy. J Cardiovasc Electrophysiol 2007;18:833-8.
35. Passman R, Kadish A. Sudden death prevention with implantable devices. Circulation 2007;31:561-71.
36. Klein G, Lissel C, Fuchs AC, Gardiwal A, Oswald H, Desousa M et al. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study. Europace 2006;8:618-24.